Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AST-VAC2 in Advanced NSCLC
NCT03371485Phase 1Completed
- Sponsor
- Cancer Research UK
- Start
- May 2018
- Primary completion
- Aug 2022
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of VAC2 in non-small cell lung cancer (NSCLC), sponsored by Cancer Research UK. Started May 2018; status: completed.
02
Drugs
VAC2
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03371485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03371485.